Metsera, Inc. (Nasdaq: MTSR) ("Metsera"), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone ...

Oil company Natural Resources and medical-device maker Beta Bionics shrug off a down market to gain in their trading debuts.

Shares of newly public Metsera (MTSR), which is developing ultra-long-acting obesity drugs, rallied 54% following a $275M initial public offering. Read more here.

Metsera, along with Maze Therapeutics, gave U.S. health care first-time share sales its best month since October.

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the ...

Shares of weight-loss drug developer Metsera surged nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm at $2.68 billion. The strong market debut of ...

Metsera, a clinical-stage biotechnology firm, debuted on the Nasdaq Global Select Market today. After initially offering its ...

The IPO comes amid a deregulatory push in the energy sector by President Donald Trump, who repeated the "drill, baby, drill" slogan in his inaugural address. Earlier this week, Sean Duffy, the newly ...

Shares of Infinity Natural Resources jumped almost 11% in their NYSE debut, valuing the oil and natural gas producer at $1.3B. The listing ...

The Financial Times reported in November that Unilever ( UL) axed a plan to sell its €15bn ice-cream business to private ...

Obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics have met their IPO expectations as the two companies prepare to join the Nasdaq this morning. | Obesity biotech Metsera and ...